Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy
Osimertinib has demonstrated efficacy against stable or asymptomatic central nervous system (CNS) metastases of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in phase 2 and 3 clinical trials that allowed prior CNS radiotherapy. However, the efficacy of...
Saved in:
| Main Authors: | Koken Ameku, Mariko Higa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/9076168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01) -
Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01) -
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01) -
Therapeutic Outcomes of Osimertinib in EGFR – Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital
by: Thi Nhu Hoa Nguyen MD, et al.
Published: (2025-05-01) -
Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study
by: Akihiro Tamiya, et al.
Published: (2025-04-01)